Corporate Governance

 

An effective Corporate Governance is crucial for the management of a company’s business affairs as well as for capital market communication. This has always been of utmost significance to Evotec. Our commitment to complying with high Corporate Governance standards is our chance to:

  • Demonstrate our dedication to well-balanced and transparent rules to the market participants and to
  • Internally emphasise the importance of our clearly defined management tools and responsibilities.

 

Declaration of Compliance by the Management Board and Supervisory Board with the German Corporate Governance Code for the year 2017 as required under sec. 161 of the German Stock Corporation Act (AktG)

The German Corporate Governance Code in its current version as of 07 February 2017 (the ‘Code’) sets forth substantial legal requirements for the management and supervision of listed German companies. The rules are based to a large extent on internationally recognized standards for sound and responsible company management.

The general key principles of sound Corporate Governance are: observance of shareholder and employee interests, effective cooperation between the Management Board and the Supervisory Board and open and transparent communication.

With the following exceptions, Evotec complies with all recommendations of the Code and the majority of the Code’s suggestions. In December 2017, Evotec’s Management Board and Supervisory Board declared in accordance with Section 161 of the German Stock Corporation Act (AktG):

Evotec AG has complied in 2017 with the recommendations of the Governmental Commission on the German Corporate Governance Code (the “Code”) as published in the official section of the Federal Gazette and intends to comply in the future with the recommendations of the Code, with the following exceptions:

  • Pursuant to Section 4.2.3 of the Code, the monetary remuneration of the Management Board members comprises fixed and variable components. Variable remuneration components consist of a one-year variable remuneration determined by a bonus scheme and a long-term so-called Share Performance Plan scheme approved by the Annual General Meetings 2012, 2015 and 2017. The Share Performance Plans have a multiple-year assessment basis that has essentially forward-looking characteristics, whereas the bonus scheme is based on the achievement of certain strategic targets set by the Supervisory Board for a certain financial year.
  • The Share Performance Plans comply with the recommendations set forth in Section 4.2.3 of the Code. In particular, they refer to specific key performance indicators and define a “Maximum Target”. However, as the issuance of awards under the Share Performance Plans 2012 and 2015 after the four-year vesting period is effected in shares, there is a cap for the number of awards upon allocation, but no other cap for the value of the allocated shares. That value will only be determined by the share price at that time. The Share Performance Plan 2017 has introduced a cap with a maximum level of 350% of the contractual issue value and therefore complies in all respects with the Code.
  • Stock options issued in existing stock option programmes before their replacement by the Share Performance Plans remain valid. While the exercise of options under these stock option programmes requires an increase of the share price, the exercise is not related to other relevant comparison parameters as recommended in Section 4.2.3 of the Code. This decision is based on the lack of relevant comparison benchmarks in the field of German Biotech at the time when the stock option programmes were created.
  • The Company’s D&O insurance and the deductible for members of the Management Board contained therein are in line with Section 3.8 of the Code and with the regulations of the Act on the Appropriateness of Management Board Compensation (VorstAG) that was enacted in 2009. However, for members of the Supervisory Board, the D&O insurance contains a “reasonable” deductible as foreseen by the version of the Code in force before its version published on 05 August 2009. The Company has decided to maintain this reasonable deductible. This decision was made in view of the Company’s interest to attract international expertise for its Supervisory Board and the fact that a deductible for non-executive directors is not very common in international practice. Whilst a lot of the German companies quoted on the TecDAX do not have a respective deductible at all, the Company believes that a reasonable deductible is a good compromise.

Hamburg, December 2017

Management Board            Supervisory Board

 

German Corporate Governance Code

The German Corporate Governance Code (the “Code”) presents essential statutory regulations for the management and supervision (governance) of German listed companies and contains internationally and nationally recognised standards for good and responsible governance. The Code aims at making the German Corporate Governance system transparent and understandable. Its purpose is to promote the trust of international and national investors, customers, employees and the general public in the management and supervision of listed German stock corporations.

Declaration of Corporate Management (§§ 289f, 315d HGB)

The actions of Evotec AG’s management and oversight bodies are determined by the principles of good and responsible Corporate Governance. In this declaration, the Management Board – also acting on behalf of the Supervisory Board – provides its report on corporate management in the Group pursuant to sections 289f, 315d of the German Commercial Code (HGB) and pursuant to subsection 3.10 of the German Corporate Governance Code. Our aim is to present our corporate management principles as clearly and concisely as possible.

Declaration of compliance and reporting on Corporate Governance

Declaration of compliance

With the following exceptions, Evotec complies with all recommendations of the Code and the majority of the Code’s suggestions. In December 2017, Evotec’s Management Board and Supervisory Board declared in accordance with Section 161 of the German Stock Corporation Act (AktG):

Evotec AG has complied in 2017 with the recommendations of the Governmental Commission on the German Corporate Governance Code (the “Code”) as published in the official section of the Federal Gazette and intends to comply in the future with the recommendations of the Code, with the following exceptions:

  • Pursuant to Section 4.2.3 of the Code, the monetary remuneration of the Management Board members comprises fixed and variable components. Variable remuneration components consist of a one-year variable remuneration determined by a bonus scheme and a long-term so-called Share Performance Plan scheme approved by the Annual General Meetings 2012, 2015 and 2017. The Share Performance Plans have a multiple-year assessment basis that has essentially forward-looking characteristics, whereas the bonus scheme is based on the achievement of certain strategic targets set by the Supervisory Board for a certain financial year.
  • The Share Performance Plans comply with the recommendations set forth in Section 4.2.3 of the Code. In particular, they refer to specific key performance indicators and define a “Maximum Target”. However, as the issuance of awards under the Share Performance Plans 2012 and 2015 after the four-year vesting period is effected in shares, there is a cap for the number of awards upon allocation, but no other cap for the value of the allocated shares. That value will only be determined by the share price at that time. The Share Performance Plan 2017 has introduced a cap with a maximum level of 350% of the contractual issue value and therefore complies in all respects with the Code.
  • Stock options issued in existing stock option programmes before their replacement by the Share Performance Plans remain valid. While the exercise of options under these stock option programmes requires an increase of the share price, the exercise is not related to other relevant comparison parameters as recommended in Section 4.2.3 of the Code. This decision is based on the lack of relevant comparison benchmarks in the field of German Biotech at the time when the stock option programmes were created. 
  • The Company’s D&O insurance and the deductible for members of the Management Board contained therein are in line with Section 3.8 of the Code and with the regulations of the Act on the Appropriateness of Management Board Compensation (VorstAG) that was enacted in 2009. However, for members of the Supervisory Board, the D&O insurance contains a “reasonable” deductible as foreseen by the version of the Code in force before its version published on 05 August 2009. The Company has decided to maintain this reasonable deductible. This decision was made in view of the Company’s interest to attract international expertise for its Supervisory Board and the fact that a deductible for non-executive directors is not very common in international practice. Whilst a lot of the German companies quoted on the TecDAX do not have a respective deductible at all, the Company believes that a reasonable deductible is a good compromise.”

The current Declaration of Compliance with the German Corporate Governance Code and the declarations of the past five years can be found on Evotec’s website (www.evotec.com) in the Investor Relations section.  

Relevant management practices and compliance

Relevant management practices

Evotec takes its Corporate Governance responsibilities very seriously. As a consequence of its shares’ listing at the Frankfurt Stock Exchange and its international shareholder base, the Company recognises not only German but also international Corporate Governance standards, insofar as German law does not explicitly stipulate otherwise. Evotec’s Management and Supervisory Boards are convinced that complying with rigorous Corporate Governance standards is of great benefit to the Company. It includes integrity in the dealings with employees, business associates, shareholders and the public, expressed in Evotec’s own exemplary conduct. As a service provider, Evotec has to win and retain the trust of its customers and business associates through impeccable behaviour. The Group’s aim is to be credible, solid and reliable and act accordingly. Thus Evotec regularly reviews and enhances its Corporate Governance practices.

Within the frame of strategical determination by the Management Board, specific goals are established and communicated. To accomplish our targets, we rely on the enterprise and initiative of our managers and employees. We achieve consensus on clearly defined objectives, and we regularly monitor how well we are meeting them. These agreements on aims are a fundamental component of our leadership philosophy and a crucial element of our remuneration system.

Code of conduct

Evotec’s corporate culture is committed to the highest standards of openness, integrity and accountability. A key element of integrity is compliance, which means adherence to both, the applicable laws and Company’s internal policies. Evotec’s commitment to a compliance-oriented culture is reflected in the Company’s Code of Conduct, which stipulates fundamental ethical principles, such as integrity and professionalism, that apply to board members and other employees alike.

The Code of Conduct sets standards for:

  • Accounting and the permissible use of the Company’s funds and assets;
  • Compliance with insider trading laws and prevention of conflicts of interest;
  • Compliance with antitrust legislation;
  • Compliance with anti-corruption laws and associated internal guidelines;
  • A work environment free of any form of discrimination and harassment
  • Non-disclosure and protection of intellectual property and business secrets; and
  • The duty to report upon the suspicion of an infringement of the Code of Conduct (whistle-blowing), except for France where such whistle-blowing will be considered in combination with the roll-out of the electronic Compliance Training.

Evotec does not tolerate any violation of applicable laws or internal policies.

The Code of Conduct is published on the Evotec website (www.evotec.com) in the Investor Relations section.

Compliance organisation

The Compliance Programme of Evotec AG is overseen by the Company’s Compliance Officer, functioning as an independent and objective body that reviews and evaluates compliance issues/concerns within the organisation and is regularly trained via a group-wide (except France) electronic Compliance Training tailored to the specific compliance issues and associated risks at the Company. The aim is to maintain permanent compliance awareness within all areas of Evotec’s business to ensure that any decision is in line with Evotec’s compliance best practices and to mitigate compliance risks. Said training is mandatory for all board members and other employees. The Company’s Compliance Officer monitors the participation in the training at regular intervals.  

The Compliance Office helps to communicate the values underlying the Code of Conduct and anchor them firmly in the Group. It ensures Group-wide implementation of the Compliance Programme.  

Another important aspect of accountability and transparency is a mechanism to enable all Evotec employees to voice concerns in a responsible and effective manner. Suspected compliance violations can be reported to an employee’s responsible line manager, the Company’s Compliance Officer or may also be reported to a worldwide compliance (whistle-blowing) hotline which is available 24 hours a day, 7 days a week. The latter can also be done anonymously, except for France where such whistle-blowing will be considered in combination with the roll-out of the electronic Compliance Training. In 2017, no reports via the central compliance hotline were registered.  

Evotec also complies with the financial market rules. The Company maintains an ad hoc Committee, which consists of the Chief Financial Officer, the General Counsel, the Head of Investor Relations and the assistant to the Board. This committee examines the ad hoc relevance of insider information and ensures that Evotec complies with the law.

Risk management

An important element of sound Corporate Governance is dealing responsibly with risks. Evotec has established an effective risk and opportunities management system that enables the Management Board to detect and react to relevant risks and market developments in good time. The Management Board reports on these to the Supervisory Board. The Company’s risk and opportunities management system and policies are covered by the annual audit of financial statements. Details can be found in the Management Report of the Evotec Annual Report (www.evotec.com, Investor Relations section). It also contains the report on the accounting-related internal control and risk management system required in accordance with the German Accounting Modernisation Act (BilMoG).  

These systems are continually developed, adjusted to match changes in overall conditions and reviewed by the auditors. The Management Board regularly informs the Supervisory Board about existing risks and the development of these risks.

Transparency

Evotec AG informs its shareholders, financial analysts, the media and the public on a regular basis about its progress. In doing so, the Company complies with all requirements of the Code regarding transparency, timeliness, openness and shareholder equality. Evotec is committed to fair disclosure of information and its communication is governed by a Company Disclosure Policy. It is a prime concern of the Company that all relevant target groups receive the same information at the same time, and this implies communicating in both English and German. The Company’s publications are available on its website www.evotec.com in the Investor Relations section.  

This section of Evotec’s website maintains information such as news releases, the financial calendar containing the publication dates of the financial statements, investor relations conferences, annual and quarterly reports, other regulatory news and regularly updated corporate governance information. This section of the website also includes the Articles of Association, the Rules of Procedure of the Supervisory Board, the Audit Committee Charter, the Code of Conduct, the Insider Trading Policy and all declarations of compliance.

Moreover, the Company website at www.evotec.com provides comprehensive information on the Evotec Group and the Evotec share. 

Accounting and auditing

On a regular basis, Evotec provides financial and business information to its shareholders and other interested parties by publishing its annual Consolidated Financial Statements and quarterly reports. As an incorporated company whose registered head office is located within the European Union, Evotec AG must prepare and publish Consolidated Financial Statements in accordance with the International Financial Reporting Standards (IFRS) whilst observing Section 315a HGB (German Commercial Code). The Consolidated Financial Statements of the Evotec Group and the financial statements of Evotec AG are audited by the audit firm and the Supervisory Board. The audit firm is appointed by the shareholders at the Annual General Meeting and commissioned by the Supervisory Board. It participates at the Supervisory Board’s deliberations on the financial statements and reports the most significant results of its audit. The Audit Committee uses this information as a guideline for its own evaluation of the statements and reports.  

The disclosed financial statements and the management reports for Evotec AG, as well as the Consolidated Financial Statements together with the consolidated management report of the Evotec Group, are audited by Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg. These audits also covered risk management and compliance with reporting requirements concerning corporate governance pursuant to section 161 of the German Stock Corporation Act. Following its consultations, the Supervisory Board also approves the financial statements and the Consolidated Financial Statements.

Working methods of the Management Board and Supervisory Board

Composition and working methods of the Management Board and Supervisory Board

According to the German Stock Corporation Act (AktG), a two-tier system with clear separation of management through the Management Board (“Vorstand”), and control through the Supervisory Board (“Aufsichtsrat”), is mandatory for German stock corporations. The Management Board is responsible for managing Evotec and representing the Company in its dealings with third parties, while the Supervisory Board appoints and dismisses the members of the Evotec Management Board and oversees the management of the Company. German law prohibits the Supervisory Board from making management decisions. The two boards, however, work closely together to achieve long-term and sustainable growth for the Company and to create shareholder value. They agree on the Company’s strategy and on business transactions that are significant. The Annual General Meeting (“AGM”; “Hauptversammlung”) is the company body representing the interests of the shareholders.

Management Board (“Vorstand”)

The Management Board of Evotec AG is responsible for the day-to-day operations of the Company and is supported by the Management Team. In its business operations and decisions, the Management Board acts on behalf of the Company and works towards its progress with the objective of sustainable creation of value, thus taking into account the interests of the shareholders, the employees and other stakeholders. The Management Board is appointed by the Supervisory Board.  

The Management Board is responsible for corporate policy, the company’s strategic orientation, financial, investment and personnel planning, resource allocation and the management of the divisions. The Management Board is responsible for preparing the quarterly Consolidated Financial Statements and the annual Consolidated Financial Statements, as well as the annual financial statements of Evotec AG. It is also responsible for the establishment of an effective risk management system, cares for compliance with legal requirements and internal guidelines.

Under Evotec’s Articles of Association, the Supervisory Board determines the size of the Management Board, which must have at least one member under the German Stock Corporation Act. The Evotec Management Board consists, in addition to the CEO, of three further board members. In accordance with a suggestion of the Code, new members are appointed for up to three years; however, prolongations of existing contracts might be up to five years as currently agreed with the Chief Executive Officer. Management Board members may be reappointed and may be dismissed with good cause prior to the termination of their terms of office. Members of Evotec’s Management Board have not accepted more than a total of three Supervisory Board mandates in non-Group listed companies or in supervisory bodies of companies with similar requirements. The Articles of Association can be found on Evotec’s website under www.evotec.com in the Investor Relations section.

With regards to diversity within the Management Board, it has to be taken into account that Evotec works in a globalised industry and has a broad and international customer base. Therefore, the Supervisory Board selects Management Board members regardless of gender, nationality or age; instead, the focus lies on their qualifications and work experience only. However, for the first time in 2015, the Supervisory Board of Evotec AG set a target quota of 0% female members on the Management Board in accordance with § 111 section 5 AktG for the time being due to the fact that new contracts have been agreed upon with all current Management Board members shortly before the entry into force of the new legislation. All of these contracts have a term extending beyond 30 June 2017. This target quota was confirmed in 2017 for a further five-year period due to the current term of the contracts of the Management Board members. In accordance with § 76 section 4 AktG, the Management Board of Evotec AG set a target quota of 30% female members in the first and second management levels below the Management Board, which were both achieved by 30 June 2017. This target quota was confirmed for a further five-year period as well.

The activities of the Management Board are regulated by its internal Rules of Procedure, which set out the matters reserved for the full Management Board, the responsibilities of the areas of responsibility and the majorities necessary for passing resolutions.

Meetings of the Management Board shall be called by the Chairman of the Board. Each member of the Management Board may request that an extraordinary meeting of the Management Board be called outside its regular meetings. The board meetings are chaired by the Chairman of the Management Board, who also coordinates the areas of responsibility. Persons who are not board members can, if so resolved by the Management Board, be admitted to board meetings in a consultative capacity.

Brief minutes have to be made of material discussions and resolutions. Resolutions of the Management Board will be carried regularly at its meetings. Resolutions may also be carried without a meeting, however, in writing, by telex or by telephone. The Management Board shall be quorate if a majority of its Members vote on a resolution. Resolutions of the Management Board shall be passed by a simple majority. Should there be a tie, the CEO shall decide.

The Management Board also provides continuous updates to the Supervisory Board through regular verbal and written reports that includes in depth analysis of the status of operations. The information provided includes written monthly management reports with extensive coverage of the Company’s financial figures for the previous month, accompanied by detailed comments and explanatory text. In addition, the Management Board must submit a budget for the following fiscal year and a plan for the medium term to the Supervisory Board. The Management Board is also required to report to the Supervisory Board in a timely fashion on any transactions that may be significant with respect to the profitability or liquidity of the Company in order to give the Supervisory Board an opportunity to express its opinion on such transactions prior to their implementation.

The Chairman of the Supervisory Board and the Chief Executive Officer as well as other members of the Management Board discussed current and ongoing topics via numerous conference calls, carried out whenever appropriate.

Details on the Management Board are provided on Evotec’s website under www.evotec.com; section ‘About’ . 

Supervisory Board (“Aufsichtsrat”)

Following the Articles of Association, the Evotec Supervisory Board consists of six members. The members of the Evotec Supervisory Board have been elected at the AGMs 2014, 2015 and 2017. Evotec’s Supervisory Board members were, in accordance with the Code’s recommendations regardless of gender, nationality or age, appointed on the basis of their qualifications, work experience, independence and diversity. 

However, the Supervisory Board has specified concrete objectives and a corresponding competence profile regarding its composition, which are ensured when making proposals to the AGM for election or re-election of new Supervisory Board members. These objectives stipulate that the activities of the Company shall be represented by having a majority of independent Supervisory Board members with national and international experience in the respective fields of (i) Research and Development, (ii) Finance, Capital markets, Legal, Corporate Governance, (iii) Marketing and Sales and Operations and (iv) Healthcare Economy/Public Health. Potential conflict-of-interest situation(s) shall be avoided by deploying the highest scrutiny when assessing potential candidates. In addition, the Supervisory Board shall ensure that the individual age of a candidate shall not exceed 72 years at the time of the proposal. Diversity with regard to female representation shall be ensured by having a target quota of 30% female members of the Supervisory Board. Finally, the Supervisory Board has agreed on two full terms as the regular limit of length of membership to the Supervisory Board. Overall, the Supervisory Board shall be composed in such a way that the majority of its members are independent and that its members as a group possess the knowledge, ability and expert experience required to properly complete its tasks. 

Currently, the composition of Evotec’s Supervisory Board fulfils all those objectives: four out of six members are independent, four nationalities are represented and there are two female members. 

Prof. Dr Wolfgang Plischke (Chairman), Bernd Hirsch (Vice Chairman), Dr Claus Braestrup and Prof. Dr Iris Löw-Friedrich are considered to be independent in accordance with Section 5.4.2 of the Code, while Elaine Sullivan is CEO of Carrick Therapeutics Ltd, a company in which Evotec AG holds 4.57% of the shares, and Michael Shalmi is Managing Director, Head of Principal Investments of Novo Holdings A/S, which is a shareholder of Evotec AG with a shareholding amounting to more than 10%. No former member of the Management Board is a member of the Supervisory Board. 

The Members of the Supervisory Board are elected by the shareholders by a simple majority of the votes cast at an Annual General Meeting. The Supervisory Board appoints a Chairman and one Vice Chairmen from among its members. The members of the Supervisory Board are elected for five years and may be re-elected. The term of the current members of the Evotec Supervisory Board will expire at the end of the AGM held in the year 2019. 

The Supervisory Board advises and oversees the Management Board in the management of the Company. Based upon regular consultations with the Management Board, the Supervisory Board is involved in strategic and planning decisions and all decisions of fundamental importance to the Company.  

Furthermore and upon request, the Supervisory Board Chair is available to discuss Supervisory Board-related issues with investors. 

In accordance with the internal rules of procedure, decisions taken by the Management Board on major transactions such as the strategic and operational direction of the Company, the annual budget, major acquisitions, investment or licence agreements, business contracts outside the Company’s ordinary course of business that have significantly different risk profiles as well as establishing new business operations or significantly revising existing business operations, require the approval of the Supervisory Board. 

The Chairman of the Supervisory Board coordinates the work in the Supervisory Board, calls and chairs its meetings and externally represents the concerns of the body.  The articles of association provide that while resolutions shall typically be passed in meetings, however, upon the Chairman’s instruction resolutions can be passed without a meeting by written notice, by telephone, facsimile, e-mail or by other conventional means of communication.

The articles of association further provide that more than half of the members of the Supervisory Board must participate in voting on a resolution to constitute a quorum. If such a quorum is not met a new meeting shall be called with a notice period of two weeks, in which case three present board members constitute a quorum. Absent members may participate in a resolution by delivering a written vote to the Supervisory Board. Unless otherwise required by law or by the articles of association, resolutions of the Supervisory Board are passed by a simple majority of the votes cast. 

The Supervisory Board has its own internal rules of procedure (see www.evotec.com; Investor Relations section) and complies with the Code’s suggestion to hold occasional separate discussions. 

The Supervisory Board was not informed about any potential conflict of interest among one of its members in the course of 2017.

 On a regular basis the Supervisory Board examines the efficiency of its activities as recommended in the Corporate Governance Code. To date all such audits have led to the conclusion that the Supervisory Board is organised efficiently and that the Management Board and the Supervisory Board interact efficiently and effectively.

An overview of its work can be found in the Report of the Supervisory Board, which can be found in the Management Report in the Evotec Annual Report on the website of the Company under www.evotec.com in the Investor Relations section.

Information on the professional affiliations of board members and on related party transactions can be found in the Annual Report of the Company. In addition, details on the Supervisory Board are provided on Evotec’s website under www.evotec.com; section ‘About’.

Work in Supervisory Board Committees

A significant proportion of the Supervisory Board’s work is conducted in committees. From among its members, Evotec’s Supervisory Board has established, pursuant to the German Stock Corporation Act and the recommendations of the Code, an Audit Committee as well as a Remuneration and Nomination Committee. Members of both committees are appointed in accordance with the Code.

For information about the composition of the Supervisory Board Committees please see the website of the Company under www.evotec.com in the Investor Relations section.

Evotec’s Audit Committee, comprising three members, supports the Supervisory Board in independently monitoring the Company’s financial reporting activities and in auditing reports. In particular, the Audit Committee scrutinises the Company’s accounting processes, the effectiveness of the internal control system and the audit. In addition, it discusses the quarterly and half-year reports with the Management Board. Within the scope of the audit of the financial statements commissioned by the Supervisory Board, the Audit Committee also discusses certain steps and procedures of the audit with the appointed auditing firm, including the auditors’ independence, the additional services rendered by the auditor, the issuing of the audit mandate to the auditing firm, the determination of auditing focal points, the fee agreement and compliance issues.

The members of the Audit Committee possess the required skills and experience. As a Chief Financial Officer, the Audit Committee’s Chairman Bernd Hirsch not only is independent, but also has the required specialist knowledge and experience in the application of accounting principles and internal control processes. Neither the Chairman of the Supervisory Board nor a former member of the Management Board may become Chairman of the Audit Committee. Evotec’s Audit Committee Charter can be found on the Company’s website (www.evotec.com) in the Investor Relations section.

The committee meets at least four times annually. The audit committee shall have a quorum if at least two of its members participate in the passing of a resolution. Resolutions require a simple majority of the votes cast. Evotec’s Audit Committee Charter can be found on the Company’s website (www.evotec.com) in the Investor Relations section.

The main duties and responsibilities of the Company’s Remuneration and Nomination Committee are to prepare the appointment of Management Board members and to prepare recommendations concerning their remuneration system and Share Performance Plan. Final decisions are made by the full Supervisory Board.

Remuneration of Board members

Evotec complies with the recommendations of the Corporate Governance Code to provide details of the remuneration of each individual member of the Management Board and the Supervisory Board. Detailed information on the remuneration of Management Board members, divided into fixed and variable compensation components as well as any fringe benefits, and remuneration of Supervisory Board members is reported in a separate section of the Management Report (“Remuneration Report”) of the Evotec Annual Report. The Evotec Annual Report is available on the website of the Company under www.evotec.com in the Investor Relations section. The remuneration of the Board Members is also publicised on Evotec’s website under www.evotec.com in the Investor Relations section. 

Evotec procured directors and officer’s liability insurance cover for its Management and Supervisory Board members, its senior management and the directors of its subsidiaries at a cost to the Company. For the members of Supervisory Board, an appropriately sized deductible, and for the members of the Management Board, a deductible in line with the stipulations of the legal provisions of the VorstAG, were agreed upon.

Shareholders and Annual General Meeting (AGM)

Evotec AG shareholders exercise their co-determination and monitoring rights at the AGM, convened at least once a year. The AGM takes decisions on all statutory matters that are binding on all shareholders and the Company. For voting on resolutions, each share confers one vote.  

All shareholders registering in due time are entitled to participate in the AGM. Evotec offers shareholders who are unable to attend the AGM the opportunity to access key parts of the event live on the internet. The Company also encourages non-attendees to exercise their voting rights by arranging independent proxies who are bound to the shareholders’ instructions. Shareholders may also authorise a person of their choice to represent them at the meeting.

The invitation to the AGM and the reports and information required for voting are published in accordance with the provisions of the German Stock Corporation Act and provided in German and English on Evotec’s website under www.evotec.com in the Investor Relations section. 

Directors’ Dealings

Under the European Market Abuse Regulation, the members of the Supervisory Board and the Management Team of Evotec as well as persons who have a close relationship with these persons are obligated to report trading in Evotec stock so far as the transactions exceed in aggregate € 5,000 (the de minimus threshold) per calendar year. In addition, Evotec has established an Insider Trading Policy (see www.evotec.com; Investor Relations section) that sets standards for board members’ and employees’ trading in Evotec shares and thus ensures transparency.

During 2017, the following Directors’ Dealings were reported:

Date
Name
Position
Type
No of items
Price
Total
15 September 2017
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
59,905
EUR 17.7711
EUR 1,064,577.75
15 September 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
55,000
EUR 17.7711
EUR 977,410.50
07 September 2017
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
48,883
EUR 16.6007
EUR 811,492.02
04 September 2017
Mario Polywka
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
43,261
EUR 15.5612
EUR 673,193.0732
23 August 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Stock option programme)
132,000
EUR 13.57
EUR 1,791,240.00
23 August 2017
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Stock option programme)
118,000
EUR 13.57
EUR 1,601,260.00
18 August 2017
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Stock option programme)
20,654
EUR 12.639
EUR 261,045.906
18 August 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Stock option programme)
11,940
EUR 12.639
EUR 150,909.66
17 August 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
55,400
EUR 14.5105
EUR 803,881.70
15 August 2017
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
28,000
EUR 12.08
EUR 338,240.00
31 March 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Stock option programme)
31,000
EUR 6.908
EUR 214,148.00
30 March 2017
Werner Lanthaler
Member of Management
Erwerb von Aktien durch Ausübung von Aktienoptionen (Stock option programme)
37,000
EUR 6.6904
EUR 247,544.80
30 March 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Stock option programme)
63,000
EUR 6.6904
EUR 421,495.20
29 March 2017
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
20,000
EUR 7.9329
EUR 158,658.00
29 March 2017
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Stock option programme)
63,000
EUR 6.7029
EUR 422,282.70
29 March 2017
Werner Lanthaler
Member of Management
Erwerb von Aktien durch Ausübung von Aktienoptionen (Stock option programme)
37,000
EUR 6.7029
EUR 240,007.30
17 February 2017
Mario Polywka
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
52,313
EUR 6.274
EUR 328,211.762
15 February 2017
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Stock option programme)
50,000
EUR 5.0868
EUR 254,340.00
Date 15 September 2017
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 59,905
Price EUR 17.7711
Total EUR 1,064,577.75
Date 15 September 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 55,000
Price EUR 17.7711
Total EUR 977,410.50
Date 07 September 2017
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 48,883
Price EUR 16.6007
Total EUR 811,492.02
Date 04 September 2017
Name Mario Polywka
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 43,261
Price EUR 15.5612
Total EUR 673,193.0732
Date 23 August 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Stock option programme)
No of items 132,000
Price EUR 13.57
Total EUR 1,791,240.00
Date 23 August 2017
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Stock option programme)
No of items 118,000
Price EUR 13.57
Total EUR 1,601,260.00
Date 18 August 2017
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Stock option programme)
No of items 20,654
Price EUR 12.639
Total EUR 261,045.906
Date 18 August 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Stock option programme)
No of items 11,940
Price EUR 12.639
Total EUR 150,909.66
Date 17 August 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 55,400
Price EUR 14.5105
Total EUR 803,881.70
Date 15 August 2017
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 28,000
Price EUR 12.08
Total EUR 338,240.00
Date 31 March 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Stock option programme)
No of items 31,000
Price EUR 6.908
Total EUR 214,148.00
Date 30 March 2017
Name Werner Lanthaler
Position Member of Management
Type Erwerb von Aktien durch Ausübung von Aktienoptionen (Stock option programme)
No of items 37,000
Price EUR 6.6904
Total EUR 247,544.80
Date 30 March 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Stock option programme)
No of items 63,000
Price EUR 6.6904
Total EUR 421,495.20
Date 29 March 2017
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 20,000
Price EUR 7.9329
Total EUR 158,658.00
Date 29 March 2017
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Stock option programme)
No of items 63,000
Price EUR 6.7029
Total EUR 422,282.70
Date 29 March 2017
Name Werner Lanthaler
Position Member of Management
Type Erwerb von Aktien durch Ausübung von Aktienoptionen (Stock option programme)
No of items 37,000
Price EUR 6.7029
Total EUR 240,007.30
Date 17 February 2017
Name Mario Polywka
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 52,313
Price EUR 6.274
Total EUR 328,211.762
Date 15 February 2017
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Stock option programme)
No of items 50,000
Price EUR 5.0868
Total EUR 254,340.00

Directors’ Shareholdings

As of 31 December 2017, the members of the Management Board and the Supervisory Board owned the following shares in the Company:

 

Shares
Stock options
Share Performance Awards
Management Board
Dr Werner Lanthaler
838,053
-
771,210
Enno Spillner
-
-
77,157
Dr Cord Dohrmann
46,218
111,814
299,956
Dr Mario Polywka
60,000
-
309,430
Supervisory Board
Prof. Dr Wolfgang Plischke
-
-
-
Bernd Hirsch
-
-
-
Dr Claus Braestrup
-
-
-
Prof. Dr Paul Linus Herrling1)
-
-
-
Prof. Dr Iris Löw-Friedrich
-
-
-
Michael Shalmi2)
-
-
-
Dr Elaine Sullivan
-
-
-
Management Board  
Shares
Stock options
Share Performance Awards
Dr Werner Lanthaler  
Shares 838,053
Stock options -
Share Performance Awards 771,210
Enno Spillner  
Shares -
Stock options -
Share Performance Awards 77,157
Dr Cord Dohrmann  
Shares 46,218
Stock options 111,814
Share Performance Awards 299,956
Dr Mario Polywka  
Shares 60,000
Stock options -
Share Performance Awards 309,430
 
Shares
Stock options
Share Performance Awards
Supervisory Board  
Shares
Stock options
Share Performance Awards
Prof. Dr Wolfgang Plischke  
Shares -
Stock options -
Share Performance Awards -
Bernd Hirsch  
Shares -
Stock options -
Share Performance Awards -
Dr Claus Braestrup  
Shares -
Stock options -
Share Performance Awards -
Prof. Dr Paul Linus Herrling1)  
Shares -
Stock options -
Share Performance Awards -
Prof. Dr Iris Löw-Friedrich  
Shares -
Stock options -
Share Performance Awards -
Michael Shalmi2)  
Shares -
Stock options -
Share Performance Awards -
Dr Elaine Sullivan  
Shares -
Stock options -
Share Performance Awards -

1) Until the AGM in June 2017 

2) Following the AGM in June 2017

 

Changes to the directors’ shareholdings will be published on Evotec website under www.evotec.com in the Investor Relations section. 

Directors' Dealings

Notification about Directors’ Dealings under article 19 European Market Abuse Regulation (MAR)

  • Information about the transaction with duty of notification
  • Description of the financial instrument: Share
  • ISIN of the financial instrument: DE000566480
 

Directors' Shareholdings

as of 30 June 2018

Shares
Stock options
Share Performance Awards
Management Board
Dr Werner Lanthaler
838,053
-
832,915
Enno Spillner
-
-
92,285
Dr Cord Dohrmann1)
46,218
111,814
318,152
Dr Mario Polywka
60,000
-
326,742
Supervisory Board
Prof. Dr Wolfgang Plischke
-
-
-
Bernd Hirsch
-
-
-
Dr Claus Braestrup
-
-
-
Prof. Dr Iris Löw-Friedrich
-
-
-
Michael Shalmi
-
-
-
Dr Elaine Sullivan
-
-
-
Management Board  
Shares
Stock options
Share Performance Awards
Dr Werner Lanthaler  
Shares 838,053
Stock options -
Share Performance Awards 832,915
Enno Spillner  
Shares -
Stock options -
Share Performance Awards 92,285
Dr Cord Dohrmann1)  
Shares 46,218
Stock options 111,814
Share Performance Awards 318,152
Dr Mario Polywka  
Shares 60,000
Stock options -
Share Performance Awards 326,742
 
Shares
Stock options
Share Performance Awards
Supervisory Board  
Shares
Stock options
Share Performance Awards
Prof. Dr Wolfgang Plischke  
Shares -
Stock options -
Share Performance Awards -
Bernd Hirsch  
Shares -
Stock options -
Share Performance Awards -
Dr Claus Braestrup  
Shares -
Stock options -
Share Performance Awards -
Prof. Dr Iris Löw-Friedrich  
Shares -
Stock options -
Share Performance Awards -
Michael Shalmi  
Shares -
Stock options -
Share Performance Awards -
Dr Elaine Sullivan  
Shares -
Stock options -
Share Performance Awards -

1) Dr Cord Dohrmann received his shares in Evotec through a transfer from an escrow account in accordance with the share purchase agreement in July 2010 in exchange for his share in DeveloGen

 

 

For a detailed description of the stock option plans and Share Performance Awards for the directors and employees of Evotec Group, please refer to the latest financial reports.

Supervisory Board committees

C = Chairman

M = Member

Initial appointment
End of tenure1)
Audit Committee
Remuneration and Nomination Committee
Prof. Dr Wolfgang Plischke (Chairman)
2014
2019
C
Bernd Hirsch (Vice Chairman)
2013
2019
C
M
Dr Claus Braestrup
2013
2019
M
Prof. Dr Iris Löw-Friedrich
2014
2019
M
Michael Shalmi2)
2017
2019
M
Dr Elaine Sullivan
2015
2019
M
Prof. Dr Paul Linus Herrling3)
2014
2017
M
Prof. Dr Wolfgang Plischke (Chairman)  
Initial appointment 2014
End of tenure1) 2019
Audit Committee
Remuneration and Nomination Committee C
Bernd Hirsch (Vice Chairman)  
Initial appointment 2013
End of tenure1) 2019
Audit Committee C
Remuneration and Nomination Committee M
Dr Claus Braestrup  
Initial appointment 2013
End of tenure1) 2019
Audit Committee M
Remuneration and Nomination Committee
Prof. Dr Iris Löw-Friedrich  
Initial appointment 2014
End of tenure1) 2019
Audit Committee M
Remuneration and Nomination Committee
Michael Shalmi2)  
Initial appointment 2017
End of tenure1) 2019
Audit Committee
Remuneration and Nomination Committee M
Dr Elaine Sullivan  
Initial appointment 2015
End of tenure1) 2019
Audit Committee
Remuneration and Nomination Committee M
Prof. Dr Paul Linus Herrling3)  
Initial appointment 2014
End of tenure1) 2017
Audit Committee
Remuneration and Nomination Committee M

1) Following the AGM in June 2019
2) 
Following the AGM in June 2017
3) 
Until the AGM in June 2017

 

Supervisory Board member
Number of Supervisory Board and committee meetings in 2017
Participation
Presence1)
Prof. Dr Wolfgang Plischke (Chairman)
8
8
100%
Bernd Hirsch (Vice Chairman)
12
11
92%
Dr Claus Braestrup
11
10
91%
Prof. Dr Paul Linus Herrling2)
4
1
25%
Prof. Dr Iris Löw-Friedrich
11
9
82%
Michael Shalmi3)
4
4
100%
Dr Elaine Sullivan
8
8
100%
Supervisory Board member Prof. Dr Wolfgang Plischke (Chairman)
Number of Supervisory Board and committee meetings in 2017 8
Participation 8
Presence1) 100%
Supervisory Board member Bernd Hirsch (Vice Chairman)
Number of Supervisory Board and committee meetings in 2017 12
Participation 11
Presence1) 92%
Supervisory Board member Dr Claus Braestrup
Number of Supervisory Board and committee meetings in 2017 11
Participation 10
Presence1) 91%
Supervisory Board member Prof. Dr Paul Linus Herrling2)
Number of Supervisory Board and committee meetings in 2017 4
Participation 1
Presence1) 25%
Supervisory Board member Prof. Dr Iris Löw-Friedrich
Number of Supervisory Board and committee meetings in 2017 11
Participation 9
Presence1) 82%
Supervisory Board member Michael Shalmi3)
Number of Supervisory Board and committee meetings in 2017 4
Participation 4
Presence1) 100%
Supervisory Board member Dr Elaine Sullivan
Number of Supervisory Board and committee meetings in 2017 8
Participation 8
Presence1) 100%

1) Commercially rounded

2) Until the AGM in June 2017

3) Following the AGM in June 2017

Remuneration of Management and Supervisory Board

Remuneration of the Management Board

The total annual compensation of the individual members of the Management Board, which is fixed by the Supervisory Board and agreed with every individual Management Board member, is composed of fixed and variable components. Variable remuneration components consist of a one-year variable remuneration determined by a bonus scheme and a long-term scheme, the so-called Share Performance Plan, which was approved by the AGM 2012, 2015 and 2017. The Share Performance Plans have a multiple-year assessment basis that has essentially forward-looking characteristics, whereas the bonus scheme is based on the achievement of certain targets set by the Supervisory Board for a certain financial year. It is guided by section 87 of the German Stock Corporation Act (AktG) and the Code. In line with those requirements, compensation is awarded based on an assessment of performance that is oriented towards the sustainable growth of Evotec. The criteria for determining the amount of compensation awarded include the tasks of the individual members of the Management Board, their personal performance, the economic situation, the performance and outlook of Evotec as well as the comparative level of compensation at peer companies and the compensation structure in place in other areas of the Company. Moreover, the Supervisory Board considers the relationship between the compensation of the Management Board and that of senior management as well as the staff overall, particularly in terms of its development over time. The Supervisory Board determines how senior managers and the relevant staff are differentiated.

Following section 4.2.3 of the Code, the amount of compensation is capped, both overall and for individual compensation components. It should be noted, however, that the variable long-term incentive compensation is based on issuance of sharebased awards under the Share Performance Plans 2012 and 2015 as approved by the AGMs in 2012 and 2015. There is a cap for the number of awards upon allocation, but no cap for the value of the allocated shares after the expiration of the vesting period. That value will only be determined by the share price at that time. The Share Performance Plan 2017 has introduced a cap with a maximum level of 350% of the contractual issue value and therefore complies with the Code in all respects.

The German Law on the Appropriateness of Management Board Compensation (VorstAG) of 31 July 2009 allows the AGM to approve the system of remunerating members of the Management Board (section 120 paragraph 4 AktG). In accordance with this regulation, the Management Board and the Supervisory Board of Evotec AG proposed such an approval at the AGM in 2012 and again in 2017. At the AGM 2017, the shareholders and shareholder representatives voted in favour of this item of the agenda with a majority of 58.60% of the votes. As outlined to the AGM, it should be noted that prior to the renewal of the management contracts in 2016, a benchmarking against biotech companies and other members of the TecDAX index has been conducted based on which both the Supervisory Board and the Management Board consider the current remuneration system and its fixed and variable components as appropriate with regards to the duties and responsibilities of the Management Board members. It should be noted that the Supervisory Board uses a performance metric to determine whether the set targets have been achieved by the Management Board members. The respective objectives are specified every year by the Remuneration and Nomination Committee of the Supervisory Board and subsequently approved by the Supervisory Board.

In 2017, the fixed and one-year variable remuneration of the active members of the Management Board totalled T€ 2,478, of which the variable part amounted to T€ 896.

Fixed remuneration includes base salaries paid in 12 monthly instalments at the end of each month and fringe benefits such as contributions to retirement insurance policies, premiums for accident and accidental death insurance policies as well as the benefit derived from the private use of an upper mid-range company car. In addition to the aforementioned remuneration, business-related payments, expenditures and expenses are reimbursed.

One-year variable remuneration is determined by a bonus scheme.

The variable portion of the remuneration paid out in March 2017 was based on the achievement of certain targets for the financial year 2016. The variable portion of the remuneration for the achievement of strategic targets for the financial year 2017 will be paid out in March 2018. In 2017, the bonus paid to Dr Werner Lanthaler, Colin Bond, Dr Cord Dohrmann, Dr Mario Polywka and Enno Spillner was based on the achievement of corporate milestones and objectives. As per 31 December 2017, the Company had accrued a total of T€ 1,066 for the variable portion of the remuneration paid to the members of the Management Board, thereof T€ 420 for Dr Werner Lanthaler, T€ 238 for Dr Cord Dohrmann, T€ 237 for Dr Mario Polywka, and T€ 171 for Enno Spillner.

The 2016 and 2017 corporate objectives related to general targets considered important for the positive development of the Company, such as the achievement of revenue and profitability targets, the execution of significant integrated collaboration agreements for both business segments and the preparation of the Company for sustainable future growth. Beyond that, specific targets included the ramp-up of an iPSC initiative in 2017 and the integration and expansion of the Cyprotex business as well as the achievement of the first milestone in the collaboration with Celgene in 2017.

In addition to their fixed and variable remuneration, the members of the Management Board received 186,984 Share Performance Awards (“SPA”) in 2017 (2016: 396,291) under the Company’s Share Performance Plan. These 2017 SPAs vest after four years depending on the achievement of defined key performance indicators over a four-year performance measurement period. SPAs can only be exercised if and when the key performance indicators are achieved. The key performance indicators for the grant in 2017 are “Share Price” and “Total Shareholder Return”, as approved by the AGM. The fair values of all SPAs granted as of the grant date amounted to a total of T€ 2,724 in 2017 (2016: T€ 1,534).

The following tables present for each Management Board member:

  • The benefits granted for the year under review including fringe benefits (such as car allowance, contributions made towards health insurance, a pension, accident/life insurance and accommodation costs) and including the maximum and minimum achievable compensation for variable compensation components
  • The allocation of fixed compensation, short-term variable compensation and long-term variable compensation for the year under review, broken down into the relevant reference years

Remuneration of the Management Board 2017

Previous Next Show fullscreen

 

The members of the Management Board of Evotec AG have only customary rights in the case of a change of control. Their contracts contain a change-of-control clause, which allows them to terminate their current contracts in the event of a change of control. Should members of the Management Board make use of their right to terminate their contracts in the event of a change of control, they are entitled to severance payments determined as follows: for Dr Werner Lanthaler, the severance payment shall be equal to 24 months of his base salary; for Dr Mario Polywka, the payment shall be equal to 18 months of his base salary; and for both Dr Cord Dohrmann and Enno Spillner, the payment shall be equal to 18 months of their base salary plus bonuses. In no case shall the respective severance payment be higher than the total compensation due for the remaining term of the respective Management Board member’s contract.

In accordance with section 4.2.3 of the Code, in case of an early termination of their respective service agreement in the absence of a change-of-control situation, payments to the members of the Management Board shall not exceed the amount of two annual remunerations and shall not exceed the amount of remuneration that would be due until the expiration date of the service agreement.

The Company has made a provision for a pension for one former Management Board member amounting to T€ 202 (2016: T€ 204). No such further provisions are due for other former Management Board members or their surviving dependants.

Remuneration of the Supervisory Board

The remuneration of the members of the Supervisory Board is stipulated in the Company’s Articles of Association.

According to section 113 AktG, Supervisory Board remuneration is to be appropriate to the task of the Supervisory Board members and the situation of the Company. The members of Evotec’s Supervisory Board are entitled to fixed payments as well as out-of-pocket expenses. In accordance with the recommendations of the Code, the Chairman and the Vice Chairman positions on the Supervisory Board as well as the Chair positions and memberships in committees are considered when determining the remuneration of individual members. Consequently, as last amended following the approval of the AGM 2014, the fixed compensation is T€ 30 per Supervisory Board member. The Chairman of the Supervisory Board is paid T€ 75, and the Vice Chairman is paid T€ 45. Supervisory Board members serving on its committees shall be paid T€ 5 per committee membership; the chairman of a committee shall be paid T€ 20.

For their contributions in 2017, the individual members of the Evotec Supervisory Board received the following compensation in 2018:

Remuneration of the Supervisory Board 2017

Total remuneration in T€1)
Prof. Dr Wolfgang Plischke
95
Bernd Hirsch
70
Dr Claus Braestrup
35
Prof. Dr Paul Linus Herrling (until 14 June 2017)
16
Prof. Dr Iris Löw-Friedrich
35
Michael Shalmi (from 14 June 2017)
19
Dr Elaine Sullivan
35
Total
305
Prof. Dr Wolfgang Plischke  
Total remuneration in T€1) 95
Bernd Hirsch  
Total remuneration in T€1) 70
Dr Claus Braestrup  
Total remuneration in T€1) 35
Prof. Dr Paul Linus Herrling (until 14 June 2017)  
Total remuneration in T€1) 16
Prof. Dr Iris Löw-Friedrich  
Total remuneration in T€1) 35
Michael Shalmi (from 14 June 2017)  
Total remuneration in T€1) 19
Dr Elaine Sullivan  
Total remuneration in T€1) 35
Total  
Total remuneration in T€1) 305

1) Cash remuneration

There are currently no consultancy agreements in place between Evotec and current or former members of the Supervisory Board.

Directors’ and Officers’ Liability Insurance (D&O Insurance)

In 2017, Evotec procured directors’ and officers’ liability insurance cover for its Management and Supervisory Board members, its senior management and the directors of its subsidiaries at a cost to the Company of T€ 74 (2016: T€ 75). An appropriately sized deductible was agreed upon for the members of the Supervisory board. The deductible agreed upon for the members of the Management Board is in line with the stipulations of the legal provisions of the VorstAG.

Share Performance Plan

To incentivise executives via variable long-term incentive compensation, the 2012, 2015 and 2017 Annual General Meetings approved the contingent capital necessary to support the so-called Share Performance Plans (SPP 2012, SPP 2015 and SPP 2017). SPP 2017 is replacing SPP 2012 and SPP 2015. However, this does not affect subscription rights issued before 14 June 2017.

The concrete design of the Share Performance Plans 2012, 2015 and 2017 lean on the concept of a share performance programme. They are characterised by the fact that participating executives are entitled to a variable remuneration in shares, when attaining a demanding target. In contrast to a common stock option programme, when attaining a target, shares are not issued in an amount that at least corresponds to the market rate of the company stock at the time of granting the subscription rights, but at the respectively lowest issue amount of currently € 1.00. The essential reason for this lies in the fact that in a Share Performance Programme, the value of the respective stock takes the place of cash compensation, so that stocks ideally should be issued without counter performance. A special economic advantage, compared to a common stock option programme, does not result for the participants as at the time the subscription rights are granted, and therefore at the outset, it is taken into consideration that the participants receive the total value of the shares (minus the respectively lowest issue amount of currently € 1.00), and not only, as in regular stock option plans, the difference between the market rate when granting subscription rights and the market rate at issue of the shares. The determination of an issue amount of currently € 1.00 is imperative from a corporate law perspective, as the issue of new shares under the respective pro-rata amount of the share capital is not permitted.

Under these plans, Share Performance Awards may be granted to a level that may result in in a total of up to 13,000,000 (4,000,000 for SPP 2012, 3,000,000 for SPP 2015 and 6,000,000 for SPP 2017) bearer shares of the Company being issued at maturity to members of the Management Board and other key employees. During the fourth quarter of 2016, a total of 793,903 SPAs (2015: 796,617 awards) were granted to the Management Board and key employees. These awards could result in a maximum of 1,587,806 bearer shares (2015: 1,593,234) being issued at maturity. This is because each Share Performance Award grants up to two subscription rights to Company shares, each of which in turn entitle the holder to the subscription of one Company share. Previous awards can be found the respective annual financial reports. The holder has to contribute € 1.00 per share at the date of issue. Share Performance Awards can only be exercised, if, when and to the extent that key performance indicators are achieved. Key performance indicators of SPP 2012 and 2015 are “Group Revenues”, “Operating Income Before Impairments”, “Net Cash Generated by Operating Activities” and “Share Price” upon which the Supervisory Board had to determine at least two per grant and define their weighting. SPP 2015 also includes the key performance indicator of “Total Shareholder Return”. Equally weighted key performance indicators of SPP 2017 are only “Share Price” and “Total Shareholder Return”.

Key parameters of the Company’s Share Performance Plan 2017 are depicted in the graphic below.

Detailed information on the Company’s current SPP 2017 as well as previous Share Performance Plans 2012 and 2015 can be found below.

Expiration of stock option schemes

SPP 2012, SPP 2015 and SPP 2017 were implemented to replace the stock option programme as the Company’s long-term incentive compensation scheme for executives. Stock options issued in existing stock option schemes I to VII remain valid.

Date of the Ordinary Annual General Meeting
Programme
07 June 1999
Programme I
26 June 2000
Programme II
18 June 2001
Programme III
07 June 2005
Programme IV
30 May 2007
Programme V
28 August 2008
Programme VI
16 June 2011
Programme VII
Date of the Ordinary Annual General Meeting 07 June 1999
Programme Programme I
Date of the Ordinary Annual General Meeting 26 June 2000
Programme Programme II
Date of the Ordinary Annual General Meeting 18 June 2001
Programme Programme III
Date of the Ordinary Annual General Meeting 07 June 2005
Programme Programme IV
Date of the Ordinary Annual General Meeting 30 May 2007
Programme Programme V
Date of the Ordinary Annual General Meeting 28 August 2008
Programme Programme VI
Date of the Ordinary Annual General Meeting 16 June 2011
Programme Programme VII

Detailed information duration of the Company’s previous stock option programmes and exercising of options can be found below.

Policies and Charters

Charters

 

Policies

Auditors

On 20 June 2018, the Annual General Meeting elected Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft to audit the financial statements and the consolidated financial statements for the fiscal year ending 31 December 2018. Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft has been serving as the Company’s auditor since 2014.

TOP